2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-U00123
    Guanoxabenz 24047-25-4 98%
    Guanoxabenz is an α2 adrenergic receptor agonist, with a Ki of 4000 nM and the fully activated form 40 nM for an α2A adrenoceptor.
    Guanoxabenz
  • HY-U00172
    Ipramidil 83656-38-6 ≥98.0%
    Ipramidil (C80-1324) is a vasodilator with significant active dilation of coronary circulation in isolated hearts. Ipramidil can cause an increase in NO release and stimulate guanylate cyclase activity.
    Ipramidil
  • HY-U00232
    Bidisomide 116078-65-0 99.62%
    Bidisomide (SC40230) is a class I antiarrhythmic agent.
    Bidisomide
  • HY-U00236
    PD0176078 248922-46-5 99.80%
    PD0176078 is a newly found N-type Calcium channel blocker.
    PD0176078
  • HY-U00308
    5-LOX-IN-4 125235-15-6 98.07%
    5-LOX-IN-4 is a 5-Lipoxygenase inhibitor extracted from patent EP 331232 A2, table 4, compound example 4.10.
    5-LOX-IN-4
  • HY-100386R
    Ticlopidine (Standard) 55142-85-3
    Ticlopidine (Standard) is the analytical standard of Ticlopidine. This product is intended for research and analytical applications. Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively.
    Ticlopidine (Standard)
  • HY-113040A
    (17R,18S)-Epoxyeicosatetraenoic acid 725246-18-4
    (17R,18S)-Epoxyeicosatetraenoic acid (17(R),18(S)-EETeTr) is a cytochrome P450 epoxygenase metabolite of eicosapentaenoic acid (HY-B0660). (17R,18S)-Epoxyeicosatetraenoic acid shows exerts negative chronotropic effects and protects neonatal rat cardiomyocytes against Ca2+ overload. (17R,18S)-Epoxyeicosatetraenoic acid has the potential for the research of antiarrhythmic agent.
    (17R,18S)-Epoxyeicosatetraenoic acid
  • HY-113469R
    Cyclic GMP (Standard) 7665-99-8
    Cyclic GMP (Standard) is the analytical standard of Cyclic GMP. This product is intended for research and analytical applications. Cyclic GMP is an endogenous second messenger that triggers interferon production in response to cytoplasmic DNA. Cyclic GMP can activate the stimulator of interferon genes (STING), activating the signaling cascade that leads to the production of type I interferons and other immune mediators. Cyclic-GMP-AMP, a conjugate of cyclic GMP and AMP, can induce IRF3 phosphorylation and nuclear translocation, enhancing antiviral immune responses. Cyclic GMP may also activate PDE to degrade cAMP, inhibit myocardial calcium current ICa, and regulate myocardial contractility. The derivative of Cyclic GMP, 8-Br-cGMP, has antiplatelet activity, and Cyclic GMP can be used in the study of antiviral immunity and cardiovascular diseases.
    Cyclic GMP (Standard)
  • HY-122489A
    (S)-Laudanosine 2688-77-9 99.95%
    (S)-Laudanosine is an alkaloid that can be found in poppies and is the S-enantiomer of Laudanosine. Laudanosine acts on the central nervous system and cardiovascular system, inhibiting low-affinity GABA receptors with an IC50 value of 10 μM, and can cause seizures, hypotension, and bradycardia. Additionally, Laudanosine exerts analgesic effects by competitively binding to the opioid Mu-1 receptor (Ki = 2.7 μM).
    (S)-Laudanosine
  • HY-128387R
    2,3-Butanediol (Standard) 513-85-9
    2,3-Butanediol (Standard) is the analytical standard of 2,3-Butanediol (HY-128387). This product is intended for research and analytical applications. 2,3-Butanediol is microbially derived compound that is a discriminating urinary biomarker of Fmo5-/- mice. 2,3-Butanediol prevents age-related increases in the plasma concentration of cholesterol. 2,3-Butanediol has potential applications in the manufacture of printing inks, perfumes, fumigants, moistening and softening agents, plasticizers, and as a carrier for pharmaceuticals.
    2,3-Butanediol (Standard)
  • HY-128747R
    α-D-Glucose-1-phosphate disodium (Standard) 56401-20-8
    α-D-Glucose-1-phosphate disodium (Standard) is the analytical standard of α-D-Glucose-1-phosphate disodium (HY-128747). This product is intended for research and analytical applications. α-D-Glucose-1-phosphate disodium is used as a starting material for synthesis of glucuronic acid. α-D-Glucose-1-phosphate disodium can be used as a cytostatic compound essential for cardiopathic therapy, as an antibiotic, as an immunosuppressive agent, and as a circulatory system therapy element.
    α-D-Glucose-1-phosphate disodium (Standard)
  • HY-13569AR
    Beraprost sodium (Standard) 496807-11-5
    Beraprost (sodium) (Standard) is the analytical standard of Beraprost (sodium). This product is intended for research and analytical applications. Beraprost sodium, a prostacyclin analog, is a stable and orally active proagent of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation. Beraprost (sodium) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Beraprost sodium (Standard)
  • HY-135735A
    Levomedetomidine hydrochloride 190000-46-5 98%
    Levomedetomidine hydrochloride is an isomer of Medetomidine (HY-17034), and a cardioprotective agent with sedative and analgesic effects.
    Levomedetomidine hydrochloride
  • HY-70037AS
    Cinacalcet-d3 hydrochloride
    Cinacalcet-d3 (hydrochloride) is the deuterium labeled Cinacalcet (hydrochloride). Cinacalcet hydrochloride (AMG-073 hydrochloride) is an orally active, allosteric agonist of Ca receptor (CaR), used for cardiovascular disease treatment.
    Cinacalcet-d3 hydrochloride
  • HY-B0317AS
    Amlodipine-d4 maleate 2714486-25-4 98%
    Amlodipine-d4 (maleate) is the deuterium labeled Amlodipine maleate. Amlodipine maleate is a dihydropyridine calcium channel blocker, acts as an orally active antianginal agent. Amlodipine maleate blocks the voltage-dependent L-type calcium channels, thereby inhibiting the initial influx of calcium. Amlodipine maleate can be used for the research of high blood pressure and cancer.
    Amlodipine-d4 maleate
  • HY-B0331AS
    Enalapril D5 maleate 349554-02-5 ≥98.0%
    Enalapril-d5 (maleate) is deuterium labeled Enalapril, which is an angiotensin converting enzyme (ACE) inhibitor.
    Enalapril D5 maleate
  • HY-B0354AR
    Urapidil hydrochloride (Standard) 64887-14-5
    Urapidil (hydrochloride) (Standard) is the analytical standard of Urapidil (hydrochloride). This product is intended for research and analytical applications. Urapidil hydrochloride is an orally active α1-adrenoceptor antagonist and 5-HT1A receptor agonist with a pIC50 of 6.13 and 4.38 against α1- and α2-adrenoceptor, respectively. Urapidil hydrochloride shows antihypertensive effect.
    Urapidil hydrochloride (Standard)
  • HY-N7032S1
    Uridine 5′-diphosphoglucose-13C6 disodium 2483735-04-0 98.35%
    Uridine 5′-diphosphoglucose-13C6 (UDP-D-Glucose-13C6) disodium is the 13C labeled Uridine 5′-diphosphoglucose disodium (HY-N7032). Uridine 5’-diphosphoglucose (UDP-glucose) disodium, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
    Uridine 5′-diphosphoglucose-13C6 disodium
  • HY-P990060
    Denecimig 2488745-86-2
    Denecimig (Mim8) is a novel activated coagulation factor VIII-mimetic human bispecific antibody with anti-FIXa and anti-FX arms that potently stimulates FX activation resulting in efficacious haemostasis in vitro and in vivo.
    Denecimig
  • HY-RS16293
    Lrp6 Mouse Pre-designed siRNA Set A

    Lrp6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Lrp6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Lrp6 Mouse Pre-designed siRNA Set A
Cat. No. Product Name / Synonyms Application Reactivity